Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)
- Status
- COMPLETED
- Phase
- PHASE2
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- Status
- TERMINATED
- Phase
- PHASE4
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
- Status
- COMPLETED
- Phase
- PHASE3
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
- Status
- COMPLETED
- Phase
- PHASE2
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
- Status
- COMPLETED
- Phase
- PHASE1
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE2